

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. PB60739	APPLICATION NO. 10/596,561
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT ALLEN, et al.			
<i>(Use several sheets if necessary)</i>		FILING DATE 16-Jun-2006		GROUP 1625	

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US-3,755,340	Aug-73	Hoehn et al.			
	US-3,833,594	Sep-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-3,833,598	Sep-74	Denzel et al.			
	US-3,840,546	Oct-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-3,856,799	Dec-74	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US 3 925 388 A	Dec-75	Hoehn et al.			
	US-3,966,746	Jun-76	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-3,979,399	Sep-76	Hoehn et al. / E.R. Squibb & Sons, Inc.			
	US-4,115,394	Sep-78	Hoehn, et al.			
	US-5,593,997	Jan-97	Dow, Koch and Schulte			
	US-2005/0043319	Feb-05	Schweighoffer and Guillet			
	US-2006/0089375A1	Apr-06	Allen, et al.			
	US-2006/0252790A1	Nov-06	Allen, et al.			
	US-2007/0111995A1	May-07	Allen, et al.			
	US 10/598973	Mar-05	Cook, et al.			
	US 10/598838	Mar-05	Christensen, IV			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No
		CA-1003419	Jan-77	Canada				
		CH-553 799	Sep-74	Switzerland				
		EP-0 076 035	Apr-83	EPC				
		EP-0 180 318	May-86	EPC				
		GB 141 7489	Dec-73	GB				
		GB 151 1006	Apr-75	GB				
		JP-2002-020386	Jan-02	Japan				
		WO-00/15222	Mar-00	PCT				
		WO-01/23389A2	Apr-01	PCT				
		WO-01/44244A1	Jun-01	PCT				
		WO-02/060900	Aug-02	PCT				
		WO-02/081463	Oct-02	PCT				
		WO-02/098878	Dec-02	PCT				
		WO-03/016563	Feb-03	PCT				
		WO-04/056823A1	Jul-04	PCT				
		WO-04/024728A2	Mar-04	PCT				
		WO-2005/058892	Jun-05	PCT				
		WO-2005/090348	Sep-05	PCT				
		WO-2005/090353	Sep-05	PCT				
		WO-2005/090354	Sep-05	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		BARE T.M. ET AL.; Synthesis and structure-activity relationships of a series of anxiolytic pyrazolopyridine ester and amide anxiolytic agents; <i>Journal of Medicinal Chemistry</i> ; 1989; 32; pages 2561-2573
		BEER B., ET AL.; "Enhancement of 3H-diazepam binding by SQ 65,396: a novel anti-anxiety agent"; <i>Pharmacology Biochemistry & Behaviour</i> ; 1978; 9; pp. 849-851
		BONDAVALLI F. ET AL; Synthesis, molecular modelling studies, and pharmacological activity of selective A1 receptor antagonists; <i>Journal of Medicinal Chemistry</i> ; 2002; 45(22); pages 4875-4887
		CHAKRAVORTI; Synthesis of Some Isoquinolylpyrazolo[3,4-b]pyridine Derivatives as Possible Antifilarial Agents; <i>Indian J. Chem.</i> ; February 1978; Vol. 16B, pp. 161-163
		CHASIN M., ET AL.; "1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009) - a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases"; <i>Biochemical Pharmacology</i> ; 1972; 21; pp. 2443-2450
		CHEMICAL ABSTRACTS REGISTRY – CAS registry number 502143-17-1 which has the laboratory code NSC 235755, 8th April 2003.
		DALY J. W. ET AL.; 1-methyl-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; <i>Medicinal Chemistry Research</i> ; 1994; 4(5); pages 293-306; Birkhaeuser; Boston US
		DAVIS A., ET AL.; "Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors"; <i>Journal of Computer-Aided Molecular Design</i> ; 1987; 1; pp. 97-119
		DE MELLO, A. ECHEVERRIA, ET AL.; Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis; <i>Journal of Medicinal Chemistry</i> ; 2004; 47(22); pages 5427-5432
		DENZEL TH.; (translation of title: NEW SYNTHESIS OF 1-UNSUBSTITUTED 1H-PYRAZOLO [3,4-b] PYRIDINE-5-CARBOXYLIC ACID ESTERS); <i>Archiv der Pharmazie</i> ; 1974; 307(3); pages 177-186
		GIEMBYCZ M.A.; Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?; <i>Drugs</i> ; 2000; 59(2); pages 193-212
		GLASS II, W. F., ET AL.; "Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors"; <i>Biochemical Pharmacology</i> ; 1979; 28; pp. 1107-1112
		HOEHN H. ET AL.; 1H-pyrazolo[3,4-b]pyridines; <i>Journal of Heterocyclic Chemistry</i> ; 1972; 9(2); pages 235-253
		HOHN H ET AL; "Potential Antidiabetic Agents. Pyrazolo63,4-b]pyridines"; <i>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US</i> , vol. 16, no. 12, 1973, pages 1340-1346, XP002097814 ISSN: 0022-2623 page 1343; compound 37
		HOROWITZ Z. P., ET AL.; "Cyclic AMP and anxiety"; <i>Psychosomatics</i> ; 1972; vol. XIII, no. 2; pp. 85-92
		KRIPALANI K. J. ET AL.; "Biotransformation in the monkey of cartazolate (SQ 65,396), a substituted pyrazolopyridine having anxiolytic activity"; <i>Xenobiotica</i> ; 1981; 11(7); pp. 481-488
		OCHIAI H. ET AL.; Discovery of new orally active phosphodiesterase (PDE4) inhibitors; <i>Chem. Pharm. Bull.</i> ; 2004 (stated to have been published online 15 June 2004); 52(9); pages 1098-1104
		OCHIAI H. ET AL.; <i>Bioorg. Med. Chem. Web Release</i> ; 2003
		OCHIAI H. ET AL.; New orally active PDE4 inhibitors with therapeutic potential; <i>Bioorg. Med. Chem.</i> ; 2004 (stated to have been available online 20 June 2004); 12(15); pages 4089-4100
		OCHIAI H. ET AL.; New orally active PDE4 inhibitors with therapeutic potential; <i>Bioorg. Med. Chem. Lett.</i> , 5th Jan 2004 issue (available as "articles in press" version on or before 4th December 2003, possibly October 2003, via internet); 14(1); pages 29-32
		PATEL J.B. AND MALICK J.B.; Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent; <i>Eur. J. Pharmacol.</i> ; 1982; 78; pages 323-333
		PATEL J.B., ET AL.; "Pharmacology of pyrazolopyridines"; <i>Pharmacology Biochemistry & Behaviour</i> ; 1985; vol. 23; pp. 675-680

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	POLSON J. B., ET AL.; "Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle"; Biochemical Pharmacology; 1979; 28; pp. 1391-1395
	RBI 1998, Catalogue no. T-112, Tracazolate"; 1998; page 340
	SABITHA, ET AL.; A Facile Route to Pyrazolo[3,4-b]Pyridines and [1]Benzopyrano[4',3'-e]Pyrazolo[3,4-b]Pyridines; Indian Institute of Chemical Technology; 1999; 29(4),655-665; Synthetic Communications; India
	SCHENONE S. ET AL.; Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands; Bioorg. Med. Chem. Lett.; 2001; 11; pages 2529-2531
	SHI D., ET AL.; Pyrazolopyridines: effect of structural alterations on activity at adenosine- and GABA-A receptors; Drug Development Research; 1997; 42; pages 41-56
	WEINRYB I., ET AL.; "Studies in vitro and in vivo with SQ-20,009: an inhibitor of cyclic nucleoside phosphodiesterase with central nervous system activity"; Excerpta Med. Int. Congr. Ser.; 1975; 359; pp. 857-865
	YU G., MASON H.J., ET. AL.; Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction; Journal of Medicinal Chemistry; 2001; 44; pages 1025-1027
EXAMINER	DATE CONSIDERED
·EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	